ge healthcare technologies inc. - GEHC

GEHC

Close Chg Chg %
71.54 -2.31 -3.23%

Closed Market

69.23

-2.31 (3.23%)

Volume: 3.53M

Last Updated:

Mar 27, 2026, 4:00 PM EDT

Company Overview: ge healthcare technologies inc. - GEHC

GEHC Key Data

Open

$71.08

Day Range

69.15 - 71.25

52 Week Range

57.65 - 89.77

Market Cap

$32.60B

Shares Outstanding

455.75M

Public Float

454.42M

Beta

1.18

Rev. Per Employee

N/A

P/E Ratio

15.72

EPS

$4.57

Yield

19.57%

Dividend

$0.04

EX-DIVIDEND DATE

Apr 2, 2026

SHORT INTEREST

N/A

AVERAGE VOLUME

3.86M

 

GEHC Performance

1 Week
 
-0.60%
 
1 Month
 
-17.85%
 
3 Months
 
-17.20%
 
1 Year
 
-13.47%
 
5 Years
 
N/A
 

GEHC Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 22
Full Ratings ➔

About ge healthcare technologies inc. - GEHC

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. It operates through the following segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment provides scanning devices, clinical applications, service capabilities, and digital solutions. The AVS segment offers screening, diagnosis, treatment, and monitoring of certain diseases. The PCS segment specializes in providing medical devices, consumables, services, and digital solutions. The PDx segment supplies diagnostic agents to the global radiology and nuclear medicine community. The company was founded in 1892. It was incorporated on May 16, 2022 and is headquartered in Chicago, IL.

GEHC At a Glance

GE Healthcare Technologies, Inc.
500 West Monroe Street
Chicago, Illinois 60661
Phone 1-833-735-1139 Revenue 20.63B
Industry Medical Specialties Net Income 2.08B
Sector Health Technology 2025 Sales Growth 4.844%
Fiscal Year-end 12 / 2026 Employees 54,000
View SEC Filings

GEHC Valuation

P/E Current 15.722
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 18.026
Price to Sales Ratio 1.821
Price to Book Ratio 3.601
Price to Cash Flow Ratio 18.91
Enterprise Value to EBITDA 12.59
Enterprise Value to Sales 2.121
Total Debt to Enterprise Value 0.239

GEHC Efficiency

Revenue/Employee 381,944.444
Income Per Employee 38,592.593
Receivables Turnover 4.253
Total Asset Turnover 0.589

GEHC Liquidity

Current Ratio 1.326
Quick Ratio 1.081
Cash Ratio 0.496

GEHC Profitability

Gross Margin 39.704
Operating Margin 14.041
Pretax Margin 13.421
Net Margin 10.104
Return on Assets 5.955
Return on Equity 22.14
Return on Total Capital 9.999
Return on Invested Capital 11.449

GEHC Capital Structure

Total Debt to Total Equity 100.809
Total Debt to Total Capital 50.202
Total Debt to Total Assets 28.35
Long-Term Debt to Equity 94.624
Long-Term Debt to Total Capital 47.121
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Ge Healthcare Technologies Inc. - GEHC

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
18.34B 19.55B 19.67B 20.63B
Sales Growth
+4.30% +6.60% +0.61% +4.84%
Cost of Goods Sold (COGS) incl D&A
11.12B 11.60B 11.52B 12.44B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
633.00M 610.00M 580.00M 578.00M
Depreciation
228.00M 248.00M 268.00M 287.00M
Amortization of Intangibles
405.00M 362.00M 312.00M 291.00M
COGS Growth
+6.81% +4.28% -0.67% +7.97%
Gross Income
7.22B 7.96B 8.15B 8.19B
Gross Income Growth
+0.66% +10.18% +2.49% +0.43%
Gross Profit Margin
+39.37% +40.69% +41.45% +39.70%
2022 2023 2024 2025 5-year trend
SG&A Expense
4.66B 5.17B 5.20B 5.29B
Research & Development
1.03B 1.21B 1.31B 1.26B
Other SG&A
3.63B 3.96B 3.89B 4.03B
SGA Growth
+6.35% +10.97% +0.58% +1.83%
Other Operating Expense
- - - -
-
Unusual Expense
(16.00M) 297.00M 310.00M 16.00M
EBIT after Unusual Expense
2.58B 2.49B 2.65B 2.88B
Non Operating Income/Expense
18.00M 448.00M 455.00M 372.00M
Non-Operating Interest Income
- - 26.00M 41.00M
-
Equity in Earnings of Affiliates
13.00M 11.00M 8.00M 3.00M
Interest Expense
86.00M 578.00M 520.00M 484.00M
Interest Expense Growth
+115.00% +572.09% -10.03% -6.92%
Gross Interest Expense
86.00M 578.00M 520.00M 484.00M
Interest Capitalized
- - - -
-
Pretax Income
2.51B 2.36B 2.58B 2.77B
Pretax Income Growth
-12.63% -6.01% +9.32% +7.25%
Pretax Margin
+13.70% +12.08% +13.12% +13.42%
Income Tax
563.00M 743.00M 531.00M 614.00M
Income Tax - Current - Domestic
493.00M 213.00M 70.00M 12.00M
Income Tax - Current - Foreign
324.00M 345.00M 412.00M 317.00M
Income Tax - Deferred - Domestic
(261.00M) 82.00M 61.00M 154.00M
Income Tax - Deferred - Foreign
7.00M 103.00M (12.00M) 131.00M
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
13.00M 11.00M 8.00M 3.00M
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
1.95B 1.62B 2.05B 2.15B
Minority Interest Expense
51.00M 46.00M 57.00M 70.00M
Net Income
1.90B 1.57B 1.99B 2.08B
Net Income Growth
-14.85% -17.18% +26.78% +4.57%
Net Margin Growth
+10.35% +8.04% +10.13% +10.10%
Extraordinaries & Discontinued Operations
- - 18.00M (4.00M)
-
Discontinued Operations
- - 18.00M (4.00M)
-
Net Income After Extraordinaries
1.92B 1.57B 1.99B 2.08B
Preferred Dividends
- - - 183.00M
-
Net Income Available to Common
1.92B 1.39B 1.99B 2.08B
EPS (Basic)
4.221 3.044 4.3706 4.5702
EPS (Basic) Growth
-13.89% -27.88% +43.58% +4.57%
Basic Shares Outstanding
453.93M 455.00M 456.00M 456.00M
EPS (Diluted)
4.221 3.024 4.3421 4.5502
EPS (Diluted) Growth
-13.89% -28.36% +43.59% +4.79%
Diluted Shares Outstanding
453.93M 458.00M 459.00M 458.00M
EBITDA
3.20B 3.40B 3.54B 3.47B
EBITDA Growth
-6.52% +6.29% +4.06% -1.75%
EBITDA Margin
+17.43% +17.38% +17.97% +16.84%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 93.471
Number of Ratings 22 Current Quarters Estimate 1.047
FY Report Date 03 / 2026 Current Year's Estimate 5.066
Last Quarter’s Earnings 1.44 Median PE on CY Estimate N/A
Year Ago Earnings 4.59 Next Fiscal Year Estimate 5.597
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 14 15 18 18
Mean Estimate 1.05 1.17 5.07 5.60
High Estimates 1.07 1.21 5.14 5.87
Low Estimate 0.92 0.98 4.86 5.32
Coefficient of Variance 3.50 4.81 1.33 2.43

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 14 13 14
OVERWEIGHT 1 1 1
HOLD 6 8 9
UNDERWEIGHT 0 0 0
SELL 1 1 0
MEAN Overweight Overweight Overweight

Insider Actions for Ge Healthcare Technologies Inc. - GEHC

Date Name Shares Transaction Value
May 20, 2025 Jeannette Bankes CEO, Patient Care Solutions 30,174 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Jeannette Bankes CEO, Patient Care Solutions 37,031 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 20, 2025 Jeannette Bankes CEO, Patient Care Solutions 18,754 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Ge Healthcare Technologies Inc. in the News